Healthcare / Drug Manufacturers - GeneralShenzhen
$10.50
+0.02 (+0.19%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-100.9M · quality 54.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
36/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$12.8B
P/E
36.2x
↑EV/EBITDA
17.5x
↑ROE
4.6%
↑Gross Margin
46.9%
↓Debt/Equity
0.27
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+10.2%
FCF CAGR
—
FCF margin
-2.0%
FCF / Net income
-0.25x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $5.13B · net income $402.0M · FCF $-100.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $5.13B | $5.13B | $5.16B | $4.07B | $3.84B |
| Net Income | $402.0M | $402.0M | $386.0M | $-551.1M | $191.2M |
| EBITDA | $825.5M | $825.5M | $793.4M | $-522.9M | $471.0M |
| EPS | 0.33 | 0.33 | 0.32 | -0.45 | 0.15 |
| Gross Margin | 46.9% | 46.9% | 47.4% | 47.8% | 48.6% |
| Operating Margin | 11.2% | 11.2% | 11.7% | 3.5% | 8.6% |
| Net Margin | 7.8% | 7.8% | 7.5% | -13.5% | 5.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.27 | 0.27 | 0.27 | 0.24 | 0.25 |
| Current Ratio | 1.34 | 1.34 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-100.9M | $-100.9M | $12.6M | $-155.5M | $-70.2M |
| Returns | |||||
| ROE | 4.6% | 4.6% | 4.5% | -6.7% | 2.2% |
| Valuation | |||||
| P/E | 36.21 | 36.21 | 32.37 | — | 81.40 |
| EV/EBITDA | 17.47 | 17.47 | 17.52 | — | 35.21 |
| P/B | 1.45 | 1.45 | 1.47 | 2.15 | 1.77 |
| Growth & Yield | |||||
| Revenue Growth | -0.5% | -0.5% | 26.8% | 6.0% | — |
| EPS Growth | 3.1% | 3.1% | 171.1% | -400.0% | — |
| Dividend Yield | 0.9% | 0.9% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
41.3%
EPS terminal req.
$0.93
Spread vs growth
-38.2%
5Y implied EPS CAGR
27.9%
EPS terminal req.
$1.13
Spread vs growth
-24.7%
10Y implied EPS CAGR
18.6%
EPS terminal req.
$1.82
Spread vs growth
-15.5%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-14.3%
Start / end P/E
38.7x → 31.8x
EPS bridge
0.32 → 0.33
Residual
-0.6%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.